Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evoximab + SBRT + Chemo Neoadjuvant for Stage II-III NSCLC
NCT06391008Phase 2Not yet recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Apr 2024
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of evoximab in non-small cell lung cancer (NSCLC), sponsored by Nanjing Drum-Tower Hospital. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
evoximab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06391008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06391008.